Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022


Company to host conference call and webcast at 8:30 a.m. EST

CARMIEL, Israel, Nov. 7, 2022 /PRNewswire/ -- Protalix Biotherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.

Protalix Biotherapeutics Logo

Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:

Date:                           Monday, November 14, 2022
Time:                           8:30 a.m. Eastern Standard Time (EST)
Toll Free (U.S.):           1-877-423-9813
International:               1-201-689-8573
Conference ID:            13734038

Webcast Details:

The conference will be webcast live from the Company's website and will be available via the following links:

Company Link:
Webcast Link:  Registration –
Conference ID: 13734038

Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.

The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Investor Contact

Chuck Padala, Managing Director
LifeSci Advisors

Logo -

Cision View original content:

SOURCE Protalix BioTherapeutics, Inc.

Company Codes: Dusseldorf:PBD, Munich:PBDA, TelAviv:PLX, Stuttgart:PBD, Berlin:PBDA, Frankfurt:PBDA, AMEX:PLX, NYSEArca:PLX

Back to news